Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants With Early Symptomatic Alzheimer's Disease

This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).

Inclusion Criteria:

• Evidence of AD pathological process, as confirmed by either amyloid positron emission tomography (PET) scan or cerebrospinal fluid (CSF)
• Mild cognitive impairment (MCI) or mild dementia due to AD
• Able to swallow whole capsules
• Body mass index (BMI) within the range of 18-34 kilograms per square metre (kg/m²) (at screening)
• Availability of an appropriate study partner

Exclusion Criteria:

• Any evidence of a condition other than AD that may affect cognition
• Participants must not have unstable or clinically significant cardiovascular disease within the last year, chronic uncontrolled hypertension, or clinically significant electrocardiogram (ECG) abnormalities
• History or presence of clinically significant cerebrovascular disease
• Clinically significant cerebral abnormalities on magnetic resonance imaging (MRI)

Note: Other protocol-defined inclusion/exclusion criteria may apply.